StockData
Cellyan Biotechnology Co., Ltd logo

Cellyan Biotechnology Co., Ltd (HKPD) company profile

HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Aug 7, 2026Score 3/30
$1.52−0.09 (-5.30%)

Close on Nov 17, 2026Market cap $24.93MP/E –Yield –

About Cellyan Biotechnology

Wholesale-Drugs, Proprietaries & Druggists' Sundries, SIC 5122

Cellyan Biotechnology Co., Ltd. operates in the supply chain services and over-the-counter pharmaceutical sectors. Through its Supply Chain Services division, the company provides logistics solutions and cross-border procurement and distribution of over-the-counter pharmaceutical products. It engages with partners across the broader logistics industry, serving commercial merchants, consumers, and large logistics providers requiring specialized pharmaceutical distribution expertise.

The company conducts substantially all of its operations in Hong Kong, where it maintains warehousing, logistics, and packaging networks supported by third-party suppliers and logistics subcontractors. Cellyan Biotechnology is an exempted holding company incorporated in the Cayman Islands, with its principal executive offices located in Kowloon, Hong Kong.

Summary of the business section of Cellyan Biotechnology's latest annual report, written by StockData.

Company profile

Company

Legal name
Cellyan Biotechnology Co., Ltd
Headquarters
Kowloon, Hong Kong
Address
Room B1, 5/F. Well Town Ind. Building, 13 Ko Fai Road, Yau Tong
Phone
(852) 26189289
Website
9zt.hk
Employees
2, Mar 31, 2026
Industry
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Incorporated in
E9
Fiscal year ends
March 31
Auditor
ONESTOP ASSURANCE PAC, Singapore

Stock & identifiers

Ticker
HKPD
Exchange
Nasdaq
IPO date
Jan 15, 2025
Shares outstanding
16M, Mar 31, 2026
Filer category
Non-accelerated filer<br>Emerging growth company
SEC CIK
2007702
CUSIP
G6365B104
FIGI
BBG01QK91KR4
Share class FIGI
BBG01QK91LS1
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Chenyu Andy LiangCEO and Director–
Zifeng WangChief Strategy Officer–
Shu LiuCFO–
Kam Leung CHANDirector–
Lap Sun WongDirector18,468
Jingyan WuDirector–
Mike Yao ZhouDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 15, 2025
Exchange
Nasdaq
First trading day
Jan 15, 2025
First-day close
$2.82
Lock-up ends (est.)
Jul 14, 2025

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“We have two employee directors, Mr.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 31, 2026Late filingNotification of late filing
Dec 17, 2025Name changeName changed from Hong Kong Pharma Digital Technology Holdings Ltd to Cellyan Biotechnology Co., Ltd
Jul 31, 2025Late filingNotification of late filing
Jan 15, 2025IPOInitial public offering priced (424B4 prospectus)
Jan 8, 2025ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?